losartan has been researched along with Parkinson Disease in 2 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grammatopoulos, TN | 1 |
| Outeiro, TF | 1 |
| Hyman, BT | 1 |
| Standaert, DG | 1 |
| Sarma, GRK | 1 |
| Kamath, V | 1 |
| Mathew, T | 1 |
| Roy, AK | 1 |
2 other studies available for losartan and Parkinson Disease
| Article | Year |
|---|---|
Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro.
Topics: alpha-Synuclein; Angiotensin II; Cell Line, Tumor; Electrophoresis, Polyacrylamide Gel; Humans; Imid | 2007 |
A case of parkinsonism worsened by losartan: a probable new adverse effect.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Dopamine Agonists; Drug Interactions; Humans; Hyperte | 2008 |